Poor responses to a test dose of subcutaneous octreotide predict the need for adjuvant therapy to achieve 'safe' growth hormone levels.


Autoria(s): Lindsay, John
Data(s)

01/10/2004

Identificador

http://pure.qub.ac.uk/portal/en/publications/poor-responses-to-a-test-dose-of-subcutaneous-octreotide-predict-the-need-for-adjuvant-therapy-to-achieve-safe-growth-hormone-levels(8db75796-2bc1-4e73-8db0-d5c3b69ac5f3).html

http://dx.doi.org/10.1007/s11102-005-1756-2

http://www.scopus.com/inward/record.url?scp=33644670829&partnerID=8YFLogxK

Idioma(s)

eng

Direitos

info:eu-repo/semantics/restrictedAccess

Fonte

Lindsay , J 2004 , ' Poor responses to a test dose of subcutaneous octreotide predict the need for adjuvant therapy to achieve 'safe' growth hormone levels. ' Pituitary , vol 7(3) , no. 3 , pp. 139-144 . DOI: 10.1007/s11102-005-1756-2

Palavras-Chave #/dk/atira/pure/subjectarea/asjc/1300/1310 #Endocrinology
Tipo

article